{"id":54103,"date":"2026-01-14T21:36:06","date_gmt":"2026-01-14T13:36:06","guid":{"rendered":"https:\/\/flcube.com\/?p=54103"},"modified":"2026-01-14T21:36:07","modified_gmt":"2026-01-14T13:36:07","slug":"fosun-kairos-inks-vitalgen-tech-deal-to-develop-in-vivo-car-t-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54103","title":{"rendered":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>Fosun Kairos<\/strong>, a subsidiary of <strong>Fosun Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>), announced a strategic cooperation agreement with <strong>Shanghai Vitalgen BioPharma Co., Ltd.<\/strong> to license two core <strong>lipid nanoparticle (LNP) technologies<\/strong>\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of <strong>in\u2011vivo CAR\u2011T therapies<\/strong> targeting autoimmune diseases such as <strong>systemic lupus erythematosus (SLE)<\/strong> and <strong>myasthenia gravis (MG)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>Fosun Kairos (Fosun Pharma subsidiary)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Shanghai Vitalgen BioPharma<\/td><\/tr><tr><td><strong>Technologies<\/strong><\/td><td>Antibody\u2011conjugated LNP &amp; Ionizable lipid<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Research, development, manufacturing, and commercialization in authorized fields<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed<\/td><\/tr><tr><td><strong>Milestones &amp; Royalties<\/strong><\/td><td>Tiered development milestones and single\u2011digit royalties on net sales<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>December\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-pipeline\">Technology &amp; Pipeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>In\u2011Vivo CAR\u2011T Innovation:<\/strong> Revolutionary technology that <strong>genetically modifies T cells directly within the patient\u2019s body<\/strong> to express Chimeric Antigen Receptors (CARs), eliminating complex external laboratory processing<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li><strong>Antibody\u2011conjugated LNP:<\/strong> Enables targeted delivery of CAR\u2011encoding nucleic acids to specific T\u2011cell subsets<\/li>\n\n\n\n<li><strong>Ionizable lipid:<\/strong> Facilitates efficient endosomal escape and payload delivery while minimizing systemic toxicity<\/li>\n\n\n\n<li><strong>First Asset:<\/strong> <strong>Dual\u2011target in\u2011vivo CAR\u2011T<\/strong> for autoimmune diseases, addressing refractory conditions with high unmet need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competition\">Market Opportunity &amp; Competition<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>SLE Patients<\/strong><\/td><td>1.0\u202fmillion<\/td><td>3.4\u202fmillion<\/td><\/tr><tr><td><strong>MG Patients<\/strong><\/td><td>150,000<\/td><td>700,000<\/td><\/tr><tr><td><strong>Refractory Cases (bio\u2011na\u00efve failures)<\/strong><\/td><td>480,000<\/td><td>2.0\u202fmillion<\/td><\/tr><tr><td><strong>In\u2011Vivo CAR\u2011T Addressable Market<\/strong><\/td><td>350,000<\/td><td>1.5\u202fmillion<\/td><\/tr><tr><td><strong>Potential Annual Cost (USD)<\/strong><\/td><td>$80,000\u2011120,000<\/td><td>$150,000\u2011200,000<\/td><\/tr><tr><td><strong>Market Value (2035E)<\/strong><\/td><td>$28\u202fbillion<\/td><td>$225\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Cabaletta Bio<\/strong> (US) \u2013 Phase\u202fI\/II for SLE\/MG using ex\u2011vivo CD19 CAR\u2011T (Nbvadilimab)<\/li>\n\n\n\n<li><strong>Kyverna Therapeutics<\/strong> (US) \u2013 KYV\u2011101 (CD19 CAR\u2011T) in Phase\u202fII for SLE<\/li>\n\n\n\n<li><strong>Fosun Kairos<\/strong> \u2013 <strong>First in\u2011vivo CAR\u2011T<\/strong> for autoimmune diseases; <strong>no competitors<\/strong> in this modality<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> In\u2011vivo approach eliminates <strong>2\u20114 week manufacturing time<\/strong>, reduces costs by <strong>60\u201170\u202f%<\/strong>, and avoids lymphodepletion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Fosun Kairos\u2019 Shanghai facility <strong>(20,000\u202fsqm)<\/strong>, currently producing COVID\u201119 therapies, will be repurposed for <strong>LNPs and in\u2011vivo CAR\u2011T<\/strong>, with <strong>GMP production<\/strong> starting Q3\u202f2026<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong><\/li>\n\n\n\n<li><strong>IND Filing:<\/strong> Q4\u202f2026 for dual\u2011target CAR\u2011T (SLE\/MG)<\/li>\n\n\n\n<li><strong>Phase\u202fI initiation:<\/strong> Q1\u202f2027<\/li>\n\n\n\n<li><strong>Phase\u202fII\/III:<\/strong> 2028\u20112030<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Fosun Kairos plans <strong>ex\u2011China licensing<\/strong> for <strong>US\/EU markets<\/strong> in 2027; Vitalgen retains rights for <strong>oncology applications<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Technology platform can be extended to <strong>other autoimmune diseases<\/strong> (rheumatoid arthritis, multiple sclerosis) and <strong>oncology<\/strong> (liquid\/solid tumors)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding technology development timelines, clinical trial initiation, and market penetration for in\u2011vivo CAR\u2011T therapies. Actual results may differ due to clinical outcomes, manufacturing scale\u2011up challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,77,4370,159,893,892,417],"class_list":["post-54103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-car-t","tag-cell-therapy","tag-fosun-kairos","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196","tag-vitalgen-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54103\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54103\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:36:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T13:36:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases\",\"datePublished\":\"2026-01-14T13:36:06+00:00\",\"dateModified\":\"2026-01-14T13:36:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103\"},\"wordCount\":427,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1401-1.webp\",\"keywords\":[\"CAR-T\",\"Cell-therapy\",\"Fosun Kairos\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\",\"Vitalgen BioPharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54103#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54103\",\"name\":\"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1401-1.webp\",\"datePublished\":\"2026-01-14T13:36:06+00:00\",\"dateModified\":\"2026-01-14T13:36:07+00:00\",\"description\":\"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54103\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1401-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1401-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54103#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54103","og_locale":"en_US","og_type":"article","og_title":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases","og_description":"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).","og_url":"https:\/\/flcube.com\/?p=54103","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-14T13:36:06+00:00","article_modified_time":"2026-01-14T13:36:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54103#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54103"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases","datePublished":"2026-01-14T13:36:06+00:00","dateModified":"2026-01-14T13:36:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54103"},"wordCount":427,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","keywords":["CAR-T","Cell-therapy","Fosun Kairos","Fosun Pharmaceutical","HKG: 2196","SHA: 600196","Vitalgen BioPharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54103#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54103","url":"https:\/\/flcube.com\/?p=54103","name":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54103#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","datePublished":"2026-01-14T13:36:06+00:00","dateModified":"2026-01-14T13:36:07+00:00","description":"Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation agreement with Shanghai Vitalgen BioPharma Co., Ltd. to license two core lipid nanoparticle (LNP) technologies\u2014antibody\u2011conjugated LNP and ionizable lipid\u2014for the development, manufacturing, and commercialization of in\u2011vivo CAR\u2011T therapies targeting autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54103#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54103"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54103#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","width":1080,"height":608,"caption":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54103#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Kairos Inks Vitalgen Tech Deal to Develop In\u2011Vivo CAR\u2011T for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1401-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54103"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54103\/revisions"}],"predecessor-version":[{"id":54105,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54103\/revisions\/54105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54104"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}